No headlines found.
Burning Rock Publishes 2025 Annual Report on Form 20-F
Globe Newswire (Tue, 28-Apr 6:45 AM ET)
Burning Rock Announces Founder's Purchase of Its ADSs
Globe Newswire (Thu, 2-Apr 6:25 AM ET)
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 12-Mar 7:08 AM ET)
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Burning Rock Biotech Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol BNR.
As of April 29, 2026, BNR stock price declined to $16.24 with 17,343 million shares trading.
BNR has a beta of 2.92, meaning it tends to be more sensitive to market movements. BNR has a correlation of 0.10 to the broad based SPY ETF.
BNR has a market cap of $166.60 million. This is considered a Micro Cap stock.
In the last 3 years, BNR traded as high as $41.72 and as low as $2.18.
The top ETF exchange traded funds that BNR belongs to (by Net Assets): PGJ, EHLS.
BNR has outperformed the market in the last year with a return of +462.9%, while the SPY ETF gained +30.5%. However, in the most recent history, BNR shares have underperformed the stock market with its stock returning -54.1% in the last 3 month period and -18.4% for the last 2 week period, while SPY has returned +2.6% and +2.5%, respectively.
BNR support price is $15.37 and resistance is $17.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNR shares will trade within this expected range on the day.
